Proximal Femur Locking Compression Plates Versus Trochanteric Nails
Launched by AO CLINICAL INVESTIGATION AND PUBLISHING DOCUMENTATION · May 21, 2010
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Patients with closed or type 1 open reverse oblique intertrochanteric fractures (AO 31 - A3) or subtrochanteric fractures (transverse fracture line, main fracture line maximum 5 cm distal from the lesser trochanter; proximal extension of fracture allowed)
- • Definitive fracture fixation with either a proximal femur locking plate or an intertrochanteric nail within 4 days after accident
- • Signed written informed consent (by the subject or legal guardian) and agreement to attend the planned FUs
- • Able to understand and read country national language at an elementary level
- Exclusion Criteria:
- • Pathologic fracture
- • Polytrauma
- • Any displacement of a femoral neck fracture
- • Additional fracture of one of the lower extremities that significantly affects the functional outcome
- • Additional injury of the lower limb that significantly affects the functional outcome
- • Fractures of the upper extremity if it affects the mobility of the patient
- • Type 2 or 3 open fracture
- • Drug or alcohol abuse
- • Active malignancy
- • ASA class V and VI
- • Inability to walk independently prior to injury
- • Neurological and psychiatric disorders that would preclude reliable assessment
- • Patient is not able to come to the regular FUs
- • Patients who have participated in any other device or drug related clinical trial within the previous month
- • Pregnancy (tested with a urine pregnancy test) or women planning to conceive within the study period
Trial Officials
Beate P. Hanson, MD
Study Director
AO Clinical Investigation and Documentation, Davos, Switzerland
About Ao Clinical Investigation And Publishing Documentation
AO Clinical Investigation and Publishing Documentation is a leading organization dedicated to advancing medical research through the rigorous evaluation of clinical trials. Specializing in the design, implementation, and dissemination of clinical studies, AO focuses on enhancing patient outcomes and contributing to the body of scientific knowledge. With a commitment to ethical standards and regulatory compliance, the organization collaborates with healthcare professionals and institutions to ensure high-quality data collection and analysis. Their expertise in publishing ensures that findings are effectively communicated to the medical community, fostering innovation and informed decision-making in patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Woolloongabba, Queensland, Australia
Chur, , Switzerland
Lucerne, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials